AI 聊天
Loading data for LFCR — first visit, this takes a few seconds.

Lifecore Biomedical, Inc.

LFCR · NasdaqGS · USD

4.12 -0.02 (-0.48%)

收盤價: Sep 17, 2026, 3:59 PM

市值
$167.3M
成交量
48.7K
下次財報日期
Nov 3, 2026

Lifecore Biomedical, Inc.(LFCR)股價、分析與資料

內在價值

正在載入內在價值…

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →
營收 (ttm)
$129.5M

正在載入...

最新財報

已通報較預期YoY 變更
營收$34.17Mn/a-2.81%
EPS-$0.19+$0.03+5.00%

下次財報

盤中。

估計 · 升級 →

查看財報詳情 →

指標

買價
3.03
市值
167M
淨利(ttm)
-34.5M
1.08
-1.27
n/a
-5.67
P/B (ttm)
-4.89
P/S (ttm)
1.29
財報日期
Nov 3, 2026
賣價
5.29
成交量
48,674
20 日平均成交量
171,427
開盤價
4.11
前收盤價
4.14
當日區間
4.10 - 4.33
52 週範圍
3.63 - 8.98
股利
n/a
除息日
n/a

關於 Lifecore Biomedical, Inc.

查看公司資料 →
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota. Drug Manufacturers - Specialty & Generic · Healthcare

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

類股 Healthcare
IPO 日期 Feb 15, 1996
員工 382
證券交易所 NasdaqGS
股票代號 LFCR